{"id":"NCT02227875","sponsor":"Mylan Inc.","briefTitle":"Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)","officialTitle":"An Open-label, Randomized, Multi-center, Parallel Group Clinical Trial Comparing the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-08","primaryCompletion":"2015-12","completion":"2015-12","firstPosted":"2014-08-28","resultsPosted":"2020-08-13","lastUpdate":"2022-03-03"},"enrollment":560,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"Mylan's insulin glargine","otherNames":[]},{"type":"DRUG","name":"Lantus®","otherNames":[]}],"arms":[{"label":"Mylan's insulin Glargine","type":"EXPERIMENTAL"},{"label":"Lantus®","type":"ACTIVE_COMPARATOR"}],"summary":"To test whether Mylan's insulin glargine once daily is non-inferior to Lantus® once daily (both administered in combination with other anti-diabetic drugs) based on the change in HbA1c from baseline to 24 weeks","primaryOutcome":{"measure":"Change in HbA1c From Baseline to 24 Weeks","timeFrame":"24 weeks","effectByArm":[{"arm":"Mylan's Insulin Glargine","deltaMin":-0.6,"sd":null},{"arm":"Lantus®","deltaMin":-0.66,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":120,"countries":["United States","Jordan","Slovakia","South Africa","South Korea","Taiwan"]},"refs":{"pmids":["34174848"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":276},"commonTop":["Hypoglycemia","Upper respiratory tract infection","Nasopharyngitis","Urinary tract infection","Headache"]}}